Ascendis PharmaASND
ASND
About: Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
Employees: 879
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
72% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 25
13% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 68
12% more capital invested
Capital invested by funds: $8.29B [Q2] → $9.32B (+$1.02B) [Q3]
8% more funds holding
Funds holding: 201 [Q2] → 217 (+16) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 17 [Q2] → 17 (+0) [Q3]
1.43% less ownership
Funds ownership: 105.38% [Q2] → 103.95% (-1.43%) [Q3]
33% less call options, than puts
Call options by funds: $39.3M | Put options by funds: $58.8M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$153
17%
upside
Avg. target
$180
37%
upside
High target
$207
58%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
UBS Eliana Merle 16% 1-year accuracy 3 / 19 met price target | 50%upside $196 | Buy Initiated | 7 Jan 2025 |
TD Cowen Yaron Werber 33% 1-year accuracy 5 / 15 met price target | 17%upside $153 | Buy Maintained | 15 Nov 2024 |
Wedbush Andreas Argyrides 26% 1-year accuracy 6 / 23 met price target | 38%upside $181 | Outperform Reiterated | 15 Nov 2024 |
Oppenheimer Leland Gershell 47% 1-year accuracy 26 / 55 met price target | 37%upside $180 | Outperform Maintained | 15 Nov 2024 |
Cantor Fitzgerald Li Watsek 18% 1-year accuracy 7 / 38 met price target | 30%upside $170 | Overweight Reiterated | 15 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
- Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update tomorrow, January 13, during the 43rd Annual J.P.
Neutral
GlobeNewsWire
2 weeks ago
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. Eastern Time / 8:15 a.m. Pacific Time in San Francisco, California.
Neutral
GlobeNewsWire
1 month ago
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once-daily, designed to provide continuous exposure to active PTH over the 24-hour dosing period. It is the first and only medicine approved by the U.S. Food & Drug Administration (FDA) for the treatment of hypoparathyroidism in adults.
Neutral
GlobeNewsWire
1 month ago
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26
- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily somatropin
Neutral
GlobeNewsWire
1 month ago
FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) in adult growth hormone deficiency (GHD) for TransCon hGH (lonapegsomatropin-tcgd; marketed as SKYTROFA® for pediatric GHD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025.
Neutral
GlobeNewsWire
1 month ago
Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets
ATHENS, Greece and ALMATY, Kazakhstan, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced that it has extended its exclusive agreement with Danish biopharmaceutical company Ascendis Pharma A/S (Nasdaq: ASND) to commercialize three rare endocrinology disease treatments in selected countries across Eurasia. Er-Kim originally announced its exclusive agreement with Ascendis to distribute these therapies across Central and Eastern Europe and Turkey in January 2024.
Neutral
Seeking Alpha
2 months ago
Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jan Mikkelsen - President & Chief Executive Officer Scott Smith - Executive Vice President & Chief Financial Officer Camilla Harder Hartvig - Head of Global Commercial Operation Joe Kelly - US General Manager Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Yaron Werber - TD Cowen Gavin Clark-Gartner - Evercore ISI Li Watsek - Cantor Fitzgerald Joseph Schwartz - Leerink Partners Vikram Purohit - Morgan Stanley Kelly Shi - Jefferies David Lebowitz - Citigroup Inc. Paul Choi - Goldman Sachs Leland Gershell - Oppenheimer Alexander Thompson - Stifel Operator Good day, and thank you for standing by. Welcome to the Ascendis Pharma Third Quarter Earnings Call.
Neutral
GlobeNewsWire
2 months ago
Ascendis Pharma Reports Third Quarter 2024 Financial Results
– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3
Neutral
GlobeNewsWire
3 months ago
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA® (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency (GHD).
Neutral
GlobeNewsWire
3 months ago
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 3-year results from the Company's ongoing Phase 2 PaTH Forward Trial of 57 adults with hypoparathyroidism showing that long-term treatment with TransCon™ PTH (palopegteriparatide; marketed as YORVIPATH®) through Week 162 drove bone remodeling into the normal range. Deficiency of parathyroid hormone is associated with low rates of bone remodeling, accumulation of overly mature bone, and higher-than-average bone mineral density that may correspond with poorer overall bone quality compared to that seen in the general population.1,2,3,4 In contrast, these results suggest that long-term palopegteriparatide treatment promotes attainment of skeletal health parameters in line with those expected with states of parathyroid sufficiency.
Charts implemented using Lightweight Charts™